Treatment

This perspective discusses allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity. The criteria presented are built upon the author’s belief that once a vaccine is developed, an initially short supply will Read More

DRUGS: Patients with chronic conditions such as rheumatoid arthritis or lupus who rely on hydroxychloroquine continue to face obstacles obtaining their medication due to increased demand for the drug as a potential COVID-19 treatment. Despite studies casting doubt on the Read More

This randomized trial showed that hydroxychloroquine did not prevent presumed/confirmed COVID-19 when used as post-exposure prophylaxis within 4 days of high- or moderate-risk COVID-19 exposure. This randomized, double-blind, placebo-controlled trial occurred across the United States and parts of Canada Enrolled Read More

This randomized clinical trial showed that convalescent plasma therapy + standard treatment did not improve time to clinic improvement within 28 days compared to standard treatment alone in patients with severe or life-threatening COVID-19.  Patients were recruited from 7 medical Read More

This is an overview of COVID-19 in older adults, who are more likely to be infected with the virus and have worse outcomes of COVID-19. Pathophysiology: Angiotensin-converting enzyme-2 (ACE-2) receptor may be a mechanism for cell entry. Since a large Read More

This small observational study found trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial. This is cause for further pharmacokinetic research regarding optimal dosage and formulation for critically ill patients.  Read More

This randomized, open-label trial found no significant difference in defined clinical outcomes between a 5 day vs 10 day course of remdesivir.  Inclusion criteria: >11 years of age, confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were Read More

THE ARTICLE DISCUSSED HAS BEEN RETRACTED. CLICK HERE TO SEE THE RETRACTION NOTICE. A multinational registry analysis found no evidence of benefit of hydroxychloroquine or chloroquine when used either alone or with a macrolide.  Using an international, observational registry across Read More

TESTING: Tennessee is taking a bold approach to testing for COVID-19, making testing available to any person who wants it, even without symptoms or specific exposure risks. Test shortages have led most states to limit availability, but Tennessee’s approach has Read More

This preliminary report from a double-blind, randomized, placebo-controlled study found remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.  Enrollment for ACTT-1 began on February 21, Read More